[{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Canntab Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Canntab Therapeutics \/ MediPharm Labs"}]

Find Clinical Drug Pipeline Developments & Deals by Canntab Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of Cannabidiol/Tetrahydrocannabinol, in 12 different strengths. MediPharm will purchase and distribute cannabis products across...

                          Product Name : Cannabidiol/Tetrahydrocannabinol-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          February 06, 2020

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : MediPharm Labs

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank